On June 10, 2025, the Second China Digital Therapy Product Quality and Regulation Seminar and the 2025 Annual Conference of the Digital Therapy Professional Committee of the China Medical Device Association were grandly held in Shanghai. This conference brought together industry experts, enterprise elites, and research experts to jointly discuss quality control and regulation construction in the field of digital therapy, drawing a new blueprint for industry development.
Collaborative efforts, building a discussion platform
This conference was hosted by the Digital Therapy Professional Committee of the China Medical Device Association, organized by the Shanghai Medical Device Inspection Institute, and received co-organizing support from Yuanwang VB100 and Fenglin International Innovation Center. At the same time, enterprises such as Suzhou Yiduo Cloud Health Co., Ltd., Shanghai Tehofen Intelligent Technology Co., Ltd., Hangzhou Zilan Health Co., Ltd., Resmed (Beijing) Trading Co., Ltd., Hui Zhi Medicine Co., Ltd., Abbott Trading (Shanghai) Co., Ltd., etc., also provided assistance for the smooth holding of the conference. Multiple parties joined hands to create this highly influential industry event.
Keynote speeches, highlighting development essentials
The Deputy Secretary-General of the China Medical Device Association, Yang Xiaofang, and the Vice President of the Shanghai Medical Device Inspection Institute, Gu Nan, attended the meeting and delivered speeches. Their speeches were based on the current industry situation, elaborating on the important position and broad prospects of digital therapy in the medical field, emphasizing the crucial significance of product quality and regulation construction for the healthy and orderly development of the industry, and pointing out the core topics and future development directions of the conference.
In the keynote speech session, many industry experts and enterprise representatives presented presentations. Zhang Zhisheng from the Shanghai Medical Device Cosmetics Review and Verification Center discussed the key points of digital therapy product review;Jiang Tianjiao, the president of Eggshell Research Institute, analyzed the industry opportunities and challenges from the perspective of market trends. Chen Peng, a senior editor of Yuanwang and a senior researcher of Eggshell Research Institute, shared innovative practice cases of digital therapy enterprises. Blaine Groat, a senior scientist of the American Pharmacopoeia Committee’s Healthcare Quality and Safety Excellence Center for Personalized Medicines, introduced international advanced experience. Lu Yiming, the co-founder and CMO of Shanghai Fudong Medical Management .Ltd, Tao Hua, the technical director of Shenzhen Meirui Medical Technology Cai Yi, the patient health management business leader of Hui Zhi China Digital Medicine Division, Fang Qiuxue, the market director of Zilan Health,and Ning Jiaqun, the human factors engineer of Shanghai Medical Device Inspection Institute, respectively, expressed their opinions from different dimensions such as technology research and development,clinical application， market promotion, and quality control, and the diverse viewpoints collided,providing rich ideas and references for industry development.
A hundred people gathered, discussing the future of the industry
More than 120 people from member enterprises of the committee and domestic digital therapy enterprises participated in this conference. The meeting was chaired by Liu Shengrong， the Secretary-General of the Digital Therapy Professional Committee of the China Medical Device Association. The on-site communication atmosphere was lively. Participants discussed in depth topics such as strategies for improving digital therapy product quality， paths for improving regulatory standards， and innovation in enterprise development models， actively offering suggestions and strategies to promote the high-quality development of the digital therapy industry. The successful holding of this conference not only strengthened communication and cooperation within the industry but also laid a solid foundation for the improvement of digital therapy product quality and regulation systems， and is of great significance for promoting China’s digital therapy industry to a new level.
Related Topics:
